Explore the multiple dimensions of ITP4-6
The complex immune dysregulation of ITP can impact platelet counts, bleeding, and quality of life1-4,7
Platelet counts <100,000/μL can indicate ITP
Platelet counts <50,000/μL can indicate severe thrombocytopenia8-10
In ITP, increased platelet clearance and decreased platelet production result in bleeding symptoms in around 60% of patients. Bleeding symptoms vary and can include9,11:
Petechiae and purpura, usually on the extremities4,12
Bleeding blisters and epistaxis4,12
Heavy menstrual bleeding4
Intracranial hemorrhage11
Severe bleeding occurs in 7% to 10% of adult patients and typically correlates with lower platelet counts.13,14*
*As seen in a cross-sectional study of 302 French patients, as well as in a systematic review of 147 clinical studies of adults and children with primary ITP.13,14
Next: ITP is about more than platelets
Learn how ITP can have a major impact on patients' quality of life.4
1. Andreescu M. The link between immune thrombocytopenia and the cytokine profile: a bridge to new therapeutical targets. Front Hematol. 2023;2:1191178. 2. Qiao J, Liu Y, Li X, et al. Elevated expression of NLRP3 in patients with immune thrombocytopenia. Immunol Res. 2016;64(2):431-437. 3. Schifferli A, Cavalli F, Godeau B, et al. Understanding Immune Thrombocytopenia: Looking Out of the Box. Front Med (Lausanne). 2021;8:613192. 4. Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188-198. 5. Kuter DJ, Gouia I, Cordoba M, et al. Clinical burden of illness in patients with persistent or chronic primary immune thrombocytopenia treated with advanced therapies in the United States. Poster presented at: American Society of Hematology Annual Meeting & Exposition; December 7-10, 2024; San Diego, CA. 6. Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013;98(1):24-33. 7. McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83(2):150-154. 8. Rovó A, Cantoni N, Samii K, et al. Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium. PLoS One. 2022;17(4):e0267342. 9. Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019;381(10):945-955. 10. Williamson DR, Albert M, Heels-Ansdell D, et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest. 2013;144(4):1207-1215. 11. Audia S, Bonnotte B. Emerging therapies in immune thrombocytopenia. J Clin Med. 2021;10(5):1004. 12. Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495-520. 13. Piel-Julian ML, Mahévas M, Germain J, et al. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost. 2018;16(9):1830-1842. 14. Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13(3):457-464.